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Tygerberg Hospital serves as the Western Cape (WC)’s only tertiary-
level acute inpatient facility for the assessment and management 
of adolescents (13 - 18 years) presenting with severe mental illness. 
A substantial number of these adolescents meet criteria for a dual 
diagnosis (defined as psychiatric disorder plus co-morbid substance 
use disorder (SUD)). The presence of these co-existing diagnoses 
prolongs initial treatment response and complicates subsequent 
intervention strategies. The current service model divides the care 
of such patients into a psychiatric inpatient treatment component 
and a separate post-discharge substance use intervention. One 
of the challenges the child and adolescent mental health (CAMH) 
service faces is the high rate of readmission of adolescents 
into psychiatric services before utilisation of community-based 
substance abuse services can even occur. Furthermore, existing 
adolescent substance abuse and rehabilitation programmes 
(offered by the Department of Social Services) do not address 
co-occurring mental illness. This situation has arisen not only 
due to a lack of evidence-based treatment guidelines for dual-
diagnosis adolescents, but also because, to date, epidemiological 
as well as clinical data for this group have not been systematically 
documented in South Africa (SA).
Background. A large number of adolescents meet criteria 
for ‘dual diagnosis’ (a psychiatric disorder plus co-morbid 
substance use disorder (SUD)), which prolongs treatment 
response and complicates intervention strategies. The current 
service model in Cape Town divides the care of such patients 
into psychiatric treatment and a separate substance use 
intervention. Child and adolescent mental health services face 
the challenge of high rates of readmission of adolescents into 
psychiatric facilities before utilisation of community-based 
substance abuse services.
Objective. There is a scarcity of available treatment guidelines 
for dual-diagnosis adolescents, and a lack of systematically 
documented epidemiological and clinical data in South African 
adolescent populations.
Method. A retrospective chart review of adolescent psychiatric 
admissions to the Tygerberg Adolescent Psychiatric Unit during 
2010 was conducted. Relevant epidemiological, clinical and 
demographic data for those presenting with a dual diagnosis 
(specifically psychotic disorders and SUD) was recorded.
Results. Results suggest a high prevalence of SUD among 
adolescents presenting with a first-episode psychosis. 
Statistically significant correlations with lower levels of 
education were found in those with ongoing substance abuse 
(specifically cannabis and methamphetamine), and a significant 
relationship between choice of debut drug and ongoing drug 
use was also demonstrated. Risk factors for SUD (psychosocial 
adversities, childhood trauma, family and community exposure 
to substances, early debut drug ages), risky sexual behaviours, 
and clinical psychiatric profiles of adolescents with dual 
diagnosis are described.
Conclusions. This cohort had an enhanced risk as a result 
of genetic vulnerability and environmental availability of 
substances, and the findings emphasise the differences in 
presentation, choice of drugs of abuse and psychosocial 
difficulties of adolescents with a dual diagnosis presenting 
to a psychiatric facility. We aim to influence role-players to 
provide more integrated services, and highlight the need for 
future prospective studies in this adolescent group to assist in 
improving outcomes.
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There is evidence that co-morbid substance use in patients 
with psychotic disorders has important implications for patient 
management, in that co-morbid SUDs are often associated with a 
variety of adverse outcomes such as treatment non-compliance, 
high rates of relapse and rehospitalisation.1 Psychosis and substance 
abuse occur together more frequently than can be explained by 
chance alone. Dixon2 reported that a substantial proportion of 
substance abusers experience psychosis, and that a SUD is one of 
the greatest obstacles to the effective treatment of people with 
schizophrenia. 
In 2008, in a large population-based study, Miettunen et al.3 
examined cannabis use and prodromal symptoms of psychosis in 
6 330 Finnish adolescents. The study concluded that cannabis use 
was associated with prodromal symptoms in adolescents and that 
this effect was not secondary to any confounding effects of other 
drugs, emotional or behavioural problems or family background. 
Furthermore, an apparent shared underlying genetic vulnerability to 
both SUD and mental illness has been well documented.4-6 Mental 
illness itself may also lead to an increase in drug-seeking behaviour 
to alleviate symptoms, while mental illness may be induced by 
substance abuse.7 Caspi et al.4 demonstrated that the presence of 
a functional polymorphism of the COMT gene is likely to moderate 
the influence of adolescent cannabis use on the development of 
psychosis in adulthood.
A significant increase in the abuse of methamphetamine in the 
WC, in addition to already high levels of alcohol and cannabis use, 
has resulted in the Tygerberg adolescent psychiatry unit seeing an 
increase in the number of patients with methamphetamine-related 
psychotic disorders presenting for admission. It has been established 
that abuse of amphetamines is associated with the development 
of schizophrenia-like symptoms (including hallucinations and 
paranoid delusions) and mood disturbances. Grelotti et al.8 describe 
patients with prolonged methamphetamine abuse being at risk 
of persistent psychotic features and showing poor response to 
antipsychotic treatment, even after stopping methamphetamine 
use. The risks for development of amphetamine-related psychosis 
include young age of onset of substance abuse, high doses of 
amphetamine, and having a family member with an amphetamine-
related psychotic disorder.8 
Risk factors for the development of a psychotic illness in adolescent 
substance abusers described in the international literature include 
severity and duration of use, age at time of first substance use, 
genetic, familial or personality vulnerabilities to the development of 
psychosis, and the type of substance used.9-11 
To the best of our knowledge, no published data currently exist for 
adolescent dual-diagnosis (psychiatric disorder with co-morbid 
SUD) populations in Africa. Our sample will therefore be the first 
demographic and clinical profile of a psychiatrically hospitalised 
South African adolescent population with dual diagnoses. The 
importance of this information lies in the need to provide 
clinical data to various role-players (departments of Health, Social 
Development and Education) involved in the planning of targeted 
intervention strategies aimed at reducing the burden of disease and 
the load on health services in the WC. 
Methods
Data collection
A retrospective chart review was conducted of all adolescents 
admitted to the Adolescent Psychiatry Inpatient Unit at Tygerberg 
Hospital between 1 January 2010 and 31 December 2010. For the 
purposes of this study, only adolescents who presented with a dual 
diagnosis, defined as the presence of a psychotic disorder with a 
co-morbid SUD (according to the Diagnostic and Statistical Manual 
of Mental Disorders, 4th edition, text revision 2000 (DSM-IV-TR)12), 
were included. 
Adolescents (aged 13 - 17 years inclusive), as well as those who 
were 18 years old but still attending school, were included in the 
study. Clinicom (the WC Department of Health data collection 
system) was used to identify the above patients. Folders were 
reviewed retrospectively and relevant data entered into a structured 
data sheet by a single investigator (AL). Data collected included 
demographic information, educational background, detailed 
drug use history, psychiatric diagnosis, co-morbid medical and 
medication history, contact with social services, forensic history, 
family history (psychiatric and substance), and documented 
stressors.
Statistical analysis
All data were entered into a single database. Descriptive statistics 
were compiled by a statistician using frequency tables, means 
and standard deviations (SDs). Cross-tabulation with the chi-
square test was used to compare categorical variables. One-way 
ANOVA was used to compare means of ordinal variables between 
groups. Statistica 10 was used for all the statistical analyses. A 5% 
significance level (p<0.05) was used as guideline for determining 
significant results.
Ethical considerations
Ethics approval was granted by the Committee for Human Research 
of Stellenbosch University (N11/01/002). The study was conducted 
in accordance with the International Committee for Harmonisation 
(ICH),13 Good Clinical Practice (GCP)14 guidelines and SA GCP,15 as 
well as the Declaration of Helsinki.16
Results
Demographic profile
Sample size. A total of 141 adolescents were admitted to the 
Tygerberg Adolescent Psychiatry Inpatient Unit during the period 
January 2010 - December 2010. Patients who were admitted more 
than once were only included once in the sample, and two folders 
contained incomplete records. The total suitable sample (number of 
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patients who fulfilled the inclusion criteria) was 75 (54%) out of 139 
complete records. 
Gender. Of the participants, 55 (73%) were male and 20 (27%) female.
Age. The age range of the sample was between 13 and 18 years, 
with a mean of 16.43 years (SD 1.002). 
Area of residence was coded according to geographical service 
areas in the WC province (Fig. 1). 
Educational status.  Of the patients 46 (61%) were not currently 
attending school. The mean highest level of education (HLOE) 
obtained was grade 8 (SD 2.19). The mean number of years out of 
school was 1.45 years (SD 1.66). 
Social history. Of the total sample, 20 (27%) had had prior contact 
with social services. One (1%) was in formal out-of-home placement, 
and 43 (57%) had a documented history of childhood abuse.
Clinical characteristics
Psychiatric presentation. For 44 (59%) of the sample, this 
admission was their first presentation to psychiatric services; 
31(41%) reported a previous psychiatric history and/or contact with 
psychiatric services.
Psychiatric diagnoses. Diagnoses on admission and discharge 
were recorded. Each diagnosis (primary and secondary) was 
counted (Tables 1 and 2). No statistically significant correlations 
could be demonstrated between diagnosis on discharge and 
any specific substances (cannabis, methamphetamine, alcohol, 
methaqualone (mandrax)).
Medical history. Of the patients 5 (7%) had a history of infection 
(any reported), 4 (5%) reported a previous head injury, and 6 (8%) 
reported a history of epilepsy.
Forensic history. Of the patients 21 (28%) had a forensic history, 47 
(63%) did not report any involvement with the law, and 7 (9%) were 
undocumented or information was missing.
Family history. Of the patients 15 (20%) were born to mothers 
who reported using illicit drugs during pregnancy, and 38 (50.7%) 
had relatives with a previous history of psychiatric disorders, 21.1% 
of which (8 cases) were related to substance use.
Sexual history. Of the patients 25 (33%) were sexually active, and 
12 (16%) reported no sexual activity. However, 38 (51%) chose not 
to reveal their sexual histories. Of those with documented sexual 
histories, only 2 (8%) reported using contraceptives. 
Stressors. Patients reported single or multiple stressors: 59 (79%) 
reported ‘relational’ factors (i.e. family conflict, divorce), as their 
major stressor, 9 (12%) had experienced a recent bereavement, 





Other (Adjustment disorder, Anxiety disorder, V code) 8
Schizophreniform disorder 7
Bipolar disorder 7
Major depressive disorder with psychosis 7
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Psychosis due to general medical condition 4
Schizo-affective disorder 3
Substance-induced mood disorder 3
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32 (43%) had a history of significant trauma (witnessed or 
experienced), 8 (11%) reported ‘homelessness’ or unstable/not 
fixed) home environment as a major stressor, 41 (55%) listed 
financial constraints as a problem at home, and 35 (47%) reported 
being bullied at school.
Substance history
Individual drug categories were recorded for cannabis, 
methamphetamine, alcohol and methaqualone. The category 
‘other’ included volatile hydrocarbons, heroin, cocaine and nicotine.
Introducer. Substances had been introduced to 52 (69%) of the 
sample by friends/peers, and to 8 (11%) by family members; 5 (7%) 
reported being introduced to drug use by both friends and family, 
and 10 (13%) chose not to reveal this information.
 
Drug debut. The debut drugs of choice and the average ages of 
drug debut were as follows: of the sample of 75 patients, 20 (27%) 
recorded more than one drug as their chosen debut drug. Drug 
debut across gender is presented in Fig. 2, while the specific ages of 
drug debut are presented in Table 3.
Fig. 2. Specific debut drugs across gender.
Table 3. Average ages of debut drug use
Number of patients 
who debuted with drug
Number of patients for 
whom age of debut was 
available
Average debut age 
(years) (based on 
available debut ages)
SD of debut age
(based on available 
debut ages)
Cannabis 54 45 14.0 1.71
Alcohol 16 10 14.2 1.55
Methamphetamine 18 15 13.8 1.78
Other 6 2 13.5 2.12
Table 4. Specific substance history
Drug history Cannabis Alcohol Methamphetamine Methaqualone Other
Average age of user (yrs) 14.11 14.33 14.08 14.38 14.00
Tested (yes) (n (%)) 45 (60) N/A 38 (51) 26 (35) N/A
Blood N/A N/A N/A N/A N/A
Urine 45 (60) 38 (51) 26 (35)
Result
   Negative 29 (39) 30 (40) 21 (28)
   Positive 10 (13) 5 (7) 1 (1)
Most frequent pattern of documented use Daily Daily Daily Irregular Daily
Ongoing use (yes) (n (%)) 57 (76) 34 (45) 35 (47) 11 (15) 13 (17)
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Rehabilitation services. No patient had had any contact with 
rehabilitation services for substance use prior to the psychiatric 
admission.
Further analyses of possible correlations between individual 
substances and categories of data (such as age, education level, 
gender, introducer, ongoing use) were performed but statistically 
significant results were limited probably owing to the small sample 
numbers and available documented information. Only statistically 
significant results for individual substances are presented below.
Specific substance history. The history of individual drug use is 
presented in Table 4.
Cannabis. There was a statistically significant relationship between 
cannabis as a debut drug and ongoing cannabis use. There was 1 
case of ongoing cannabis use (25%) in the ’unknown debut drug’ 
group, as opposed to 8 (100%) of those who did not debut with 
cannabis, and 45 (83%) of those who did debut with cannabis, 
reporting ongoing cannabis use (p=0.00013). The difference 
between HLOE reached in those with ongoing cannabis use and 
those who did not currently use cannabis was statistically significant 
(p=0.02): the mean HLOE reached in patients with ongoing cannabis 
use was grade 8 (SD 0.270), compared with grade 9 in those who did 
not currently use cannabis.
Methamphetamine. The difference in HLOE between patients 
with ongoing methamphetamine use and those who did not 
currently use methamphetamine was statistically significant 
(p=0.04). The mean HLOE in patients with current use was grade 7.6 
(SD 0.349) compared with grade 8.4 in non-users (SD 0.625).
Alcohol. The difference between males and females with regard 
to reporting of alcohol as debut drug was statistically significant 
(p=0.013). A greater proportion of girls (45%) reported using 
alcohol as their debut drug, while only 12% of males admitted 




Substance abuse among adolescents in South African 
communities is an escalating problem. Studies of South African 
adolescent school-going populations17 and psychiatric inpatient 
populations18,19 have highlighted the scarcity of clinical and 
demographic data concerning at-risk youth. Such data are urgently 
needed to inform substance abuse prevention and intervention 
strategies. Accounting for over half (54%) of the total admissions 
to the Tygerberg Adolescent Inpatient unit over a year, this sample 
highlights the very high occurrence of co-morbid substance use 
in adolescents presenting with a psychotic episode. Our figures 
are in keeping with international figures that suggest a higher 
prevalence of SUD among adolescents presenting with a first-
episode psychosis than among adults with schizophrenia (20 - 75% 
v. 20 - 50%).20 Several theories have been put forward to account for 
the increased prevalence of SUD in this population group, including 
a ‘self-medication’ hypothesis, bi-directional genetic-environmental 
vulnerability, psychosocial influences and peer group/academic 
stressors.6,4,21 
This sample group was collectively representative of the adolescent 
population across the WC, as evidenced by the geographical 
distribution in Fig. 1. The area categorised as ‘northern suburbs’ has 
a greater representation, since Tygerberg serves as both district and 
regional hospital for this area specifically, and as the tertiary hospital 
for all other areas in the WC.
Educational status
An alarming 61% of adolescents in our sample were not currently 
attending or enrolled in school, with an average of 1.45 years out 
of school, in keeping with local data on non-psychotic substance-
using teenagers, who also have poor scholastic histories. A 
longitudinal study conducted in Cape Town high schools over 2 
years found an association between poor academic performance, 
school drop-out and alcohol use (particularly binge drinking).22 A 
worrying statistically significant association was demonstrated with 
HLOE achieved in relation to specific debut drugs (cannabis and 
methamphetamine) and ongoing use of these drugs. Ongoing use 
of cannabis, which is currently the most common drug of abuse 
among youth under age 20 in the WC,23 was associated with a 
lower educational level reached (grade 8), while ongoing use of 
methamphetamine (the second most commonly used illicit drug 
in youth under 20 in the WC23) was also associated with a lower 
level of education (grade 7.6). This highlights that currently drug-
using psychotic adolescents are achieving lower levels of education 
and literacy, which may have longer-term implications for mental 
health outcomes, high-risk behaviours and compliance. In addition, 
not only are these adolescents further intellectually vulnerable 
as a result of their drug choice, but cannabis is well known to 
contribute to psychotic vulnerability and expression of psychosis in 
adolescence.24,25 
Social status and stressors
Only 27% of the subjects were known to social services, and 
just 1% was in official out-of-home placement. Given the high 
proportion (57%) who reported a history of childhood abuse and 
an even greater percentage (79%) admitting to ‘relational/family’ 
factors being major stressors, greater involvement of social services 
would have been expected. It has been well documented in the 
local26 as well as the international literature that the major factors 
influencing early youth exposure to and ongoing use of substances 
include domestic psychosocial stressors and family drug use, as 
well as community regulatory norms that encourage substance 
experimentation.23 Van Hasselt et al.27 also reported the associated 
risk between childhood maltreatment (especially physical and 
sexual abuse) and earlier onset of substance use.
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Furthermore, substance abuse treatment centres are primarily 
under the aegis of the Department of Social Development in SA, 
with contributions from various other sectors such as Justice, 
Health and Education. Concerns regarding the poor integration of 
cross-sectoral services (such as Health and Social Development) 
have been raised in many fora (unpublished Central Drug Authority 
report, September 2011). Many of the youth presenting at a 
tertiary level with a dual diagnosis are reported to have been 
unable to access substance treatment centres easily because of 
their co-existing psychiatric disorder. Adolescents with psychosis 
are often not accepted into facilities for rehabilitation until their 
‘psychotic illness’ has been treated, which is problematic, given 
the complex relationship between ongoing substance use and 
persistence of psychotic symptoms. Dual diagnosis as a barrier 
to accessing treatment for substance use is also reported in 
developed countries such as the USA.28 In our sample no patient 
had had contact with a rehabilitation centre before the current 
admission. Limited or restricted access to rehabilitation services 
further compromises this already difficult-to-treat population. This 
situation further highlights the poor integration of current services 
and underlines the urgency for greater collaboration between the 
Health and Social Development sectors. 
Clinical psychiatric profile
Psychiatric diagnoses are documented in Tables 1 and 2. Of 
the sample 59% presented with a ‘first episode’ of psychosis, a 
population at particularly high risk, given that this is the age 
at which major psychiatric disorders such as schizophrenia are 
usually expressed for the first time. Substance abuse at this stage 
creates diagnostic difficulties, in that many substances (such as 
cannabis and methamphetamine) may present with a clinical 
picture that mimics symptoms of major psychiatric disorders such 
as schizophrenia. This complicates intervention, in that the clinician 
may be uncertain whether to allow a medication-free period before 
treating the psychosis and risk a longer duration of untreated 
psychotic illness (an indicator of poor prognosis) or to treat 
(perhaps unnecessarily) the patient with antipsychotic medication 
that has its own potentially serious complications in adolescence. 
This diagnostic difficulty is evidenced again by the diagnosis of 
‘substance-induced psychotic disorder’ given to 55% of patients 
on admission, and retained in only 24% on discharge. A similar 
measure of the co-morbidity of an Axis 1 disorder of psychosis and 
a co-morbid SUD was found in 28.6% of the sample described by 
Paruk et al.18 in a KwaZulu-Natal adolescent cohort.
Further analysis of the significance of the change in diagnoses 
from admission to discharge would have been useful, but was not 
possible given the sample size and documentation validity. More 
than half of the sample had the co-morbidity of ‘poly-substance 
abuse’, which highlights the reality that these adolescents are 
experimenting with and using more than one illicit drug, which may 
further complicate diagnostic clarity. The diagnosis of schizophrenia 
was made in 21% of the sample, indicating the presence of severe 
mental illness in a high-risk substance-abusing population, with 
multiple confounding influences (such as genetic vulnerability, early 
trauma exposure), poor social support structures, low education 
levels and forewarning of future high levels of psychiatric morbidity. 
A positive psychiatric family history is important in the diagnosis 
and prognosis of mental illness in adolescents. Of this sample 20% 
had early-life exposure to illicit substances by mothers who misused 
substances during their pregnancy. According to a study by Zammit 
et al.,29 adverse effects on the fetus as a result of maternal use of 
substances (such as tobacco and alcohol) during pregnancy may 
increase the risk of psychopathology in the child. In particular, there 
was a non-linear association between use of more than 21 units of 
alcohol per week by mothers and the development of psychotic 
symptoms in their offspring. This study does not include specific 
maternal substance use history, but it would be useful to include 
this in future studies.
Half (50.7%) of the study sample had relatives with a psychiatric 
history, which in 21.1% of cases was related to substance use. We 
know that one of the major risk factors for early drug experimentation 
is exposure to substances at an early age by substance-abusing 
parents and family members.30 Our cohort is therefore at enhanced 
risk for dual diagnosis as a result of both genetic vulnerability, as 
evidenced by a family history of mental illness, and an environment 
characterised by easy availability of substances.
This study also echoes a growing concern that HIV/AIDS awareness 
programmes targeted at youth may not be having the desired effect. 
Risky sexual behaviour in adolescence is often a result of impaired 
judgement, impulsivity, previous early sexual assault and substance 
abuse. Substance abuse may decrease sexual inhibition and further 
impair judgement, increasing this risk. Of our sample 51% did not 
disclose their sexual histories, which raises concerns about sexual 
experimentation and promiscuity, and 8% of those who did admit 
to being sexually active did not have protected sex. Engaging 
in unprotected sex and multiple casual sexual relationships are 
associated with unplanned pregnancies (and possibly school 
drop-out) and increased rates of sexually transmitted diseases 
including HIV. According to Plüddemann et al.,31 adolescents who 
drink alcohol and/or use other drugs are more likely to be sexually 
active than are those who do not, and also more likely to engage 
in unprotected sex. In addition to this risk, our sample may be at 
greater cumulative risk of cognitive and judgement impairment 
as a result of the psychotic illness. This may highlight the need for 
more aggressive substance and sexual education to be addressed at 
health care centres, in particular mental health settings. 
Previous studies have suggested that substance abuse in adolescence 
is associated with an increased risk of multiple experiences of violence 
and crime.32 In our sample, however, only 28% reported interaction 
with the law, while 63% had no forensic history. One may speculate 
that this may have been influenced by police involvement being 
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a feature only of more serious offences, or that the presence of a 
possible mental illness resulted in re-routing of the adolescent into 
the health rather than the criminal justice system.
Substance history
Adolescents in this sample were primarily introduced to substances 
by peers and friends (69%). This is in keeping with other local 
studies,22,26 which report that adolescents are more likely to use 
substances if they are available and used by their immediate circle 
of friends, especially if they are influenced by peer pressure. Of note, 
47% of our cohort admitted to being bullied at school; this may 
have included peer pressure to experiment with drugs in addition 
to directed aggression.
Cannabis was the most common debut drug across the genders 
(Fig. 2), although 26% reported more than one debut drug. This 
differs from the finding of Flisher et al.17 that a non-clinical sample 
of Cape Town high-school learners who used cannabis were more 
likely to have debuted with alcohol or tobacco first. A possible 
reason for the difference in findings from Flisher’s study may be 
the smaller sample number in this study, but it is possible that in a 
particularly vulnerable cohort of psychotic adolescents, psychiatric 
symptoms may have pre-dated the substance use, and that 
cannabis as a debut drug may have been used to self-medicate 
early psychotic symptoms. Cannabis use to self-medicate early and 
prodromal symptoms is well described in the literature.4,6 
In this sample a greater number of females (45%) than males 
reported alcohol as a debut drug. Alcohol is often considered 
more ‘socially acceptable’ than other drugs and is readily accessible 
even in impoverished communities of the WC, a province well 
known for its wine production. As a result, alcohol may not be 
considered a ‘drug’ by many, and this could be the reason for the 
low reporting among males. Interestingly, 40% of males could not 
recall when they had started using alcohol. This is in contrast to the 
high prevalence of ‘self-reported’ drug use (including alcohol) in a 
KwaZulu-Natal cohort of general adolescent psychiatric inpatients.18 
Again it could be hypothesised that the dual-diagnosis cohort is 
additionally impaired by their psychotic presentations, and this may 
influence the differences noted in self-reporting and recall.
A surprising finding was that debut drug ages (Table 3) were higher 
than expected when compared with national figures (unpublished 
Central Drug Authority report, September 2011), which suggest 
that the average age of substance dependence is 12 years and 
falling. For cannabis and methamphetamine, the two most abused 
drugs in the WC, the average debut ages were 14 years and 13.8 
years, respectively. It is important to note that differences in figures 
between a clinically psychiatrically ill cohort (this study sample) and 
a national non-psychiatric sample may indicate a different cause 
and pathogenesis for the SUD, and a different type of substance 
abuse intervention programme may therefore be required in a dual-
diagnosis population of adolescents. 
Referring to Table 4, which records specific drugs and their patterns 
of use in the sample, cannabis once again featured as the most 
commonly used drug among adolescents with dual diagnosis. This 
is similar to results from a study by Latt et al.,33 which also found 
cannabis to be the commonest illicit drug abused by patients with 
psychosis (schizophrenia and other psychotic disorders) presenting 
acutely to the emergency department. An important finding is 
the statistically significant relationship between cannabis as a 
debut drug and ongoing cannabis use. Pencer et al.34 reported a 
higher rate of cannabis use at baseline and at 2-year follow-up in 
adolescents with first-episode psychosis compared with adults. 
It further raises the possibility that this population of substance-
abusing psychotic adolescents may represent a group different 
to the general adolescent population in SA, that may therefore 
require more effective inter-sectoral collaboration and interventions 
that target SUD specifically associated with psychotic/psychiatric 
illnesses.
Limitations
As this was a retrospective chart review, the quality of the clinical 
notes could not be standardised as they were recorded by different 
doctors at different levels of training. The data were however 
captured by a single investigator to ensure uniformity. The small 
sample size limited the statistical analysis, and the severity of illness 
in the population described may limit generalisation to other 
adolescent populations.
Conclusion
This review emphasises differences in presentation, choice of drugs 
of abuse and psychosocial difficulties of adolescents with a dual 
diagnosis presenting to a tertiary psychiatric facility. The findings 
highlight the need for integrated services, particularly collaboration 
between health and social development, given the influence of 
risk factors such as psychosocial adversity, child abuse, community 
exposure to substances, and poor academic performance on a 
psychiatrically vulnerable adolescent population. Mental illness 
may be a significant barrier to access to SUD services for these 
adolescents, and lack of professional and managerial awareness 
of the complexity of SUD co-existing with psychotic disorders 
may lead to poorer outcomes and an eventual increase in the 
burden of disease. It is important that all stakeholders involved in 
the planning and delivery of services consider these findings as 
an indication both of the need for appropriate interventions for 
this specific group of substance users and of the current strain 
on adolescent psychiatric inpatient services in the WC. This study 
highlights the need for future prospective studies to focus on this 
particular population group and contribute to the literature on 
factors influencing outcome, risk and vulnerability in local samples 
of adolescents with a dual diagnosis.
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